RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Gilead Sciences was granted China approval for its once-daily novel three-in-one oral treatment for HIV. Biktarvy® is a combination of a novel, unboosted integrase strand transfer inhibitor (INSTI), bictegravir, with the two-drug treatment Descovy® (emtricitabine and tenofovir alafenamide). Biktarvy was approved in the US and EU in 2018. Gilead was not required to conduct specific China tests, but based its filing on four Phase III global studies that enrolled a diverse population of 2,414 HIV-1 infected patients. Source: China Biotoday
